Genome & Company Amends Stock Option Grant: Exercise Price Cut 70%, Shares Increased

Amendment to stock option grant filed on March 2022 (amendment date: May 14, 2026)
Reason: Exercise price adjustment due to capital increase (contract clause 5)
Key changes: Granted shares from 89,000 to 95,000; exercise price from 26,670 won to 7,860 won (approx. 70% reduction)
Total outstanding options: from 1,941,396 to 4,092,568 (including new grants, exercises, etc.)
Grantees: 22 employees (including Park Hyun-woo with 20,000 shares); names omitted for individuals with less than 0.1% of total shares